Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jean-Daniel Bonny is active.

Publication


Featured researches published by Jean-Daniel Bonny.


Journal of Controlled Release | 2001

In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum

Ingo Alberti; Yogeshvar N. Kalia; Aarti Naik; Jean-Daniel Bonny; Richard H. Guy

PURPOSE The objective of this study was to evaluate, using attenuated total reflectance Fourier transform infrared spectroscopy, the stratum corneum (SC) bioavailability of terbinafine (TBF) following topical treatment with four different formulations. METHODS Four skin sites on the ventral forearms of five healthy volunteers were treated for 2 h using one of four formulations based on a vehicle consisting of 50% ethanol and 50% isopropyl myristate. Three of these formulations included a percutaneous penetration enhancer: either 5% oleic acid, 10% 2-pyrrolidone or 1% urea. The SC concentration profile of TBF was measured by repeated infrared spectroscopic measurements while sequentially stripping off the layers of this barrier membrane with adhesive tape. This method was validated by HPLC analysis of TBF extracted from the stripped tapes. Transepidermal water loss (TEWL) measurements were also performed, to permit facile estimation of SC thickness. RESULTS The SC concentration profiles of TBF were fitted to the appropriate solution of Ficks second law of diffusion, thereby allowing determination of the characteristic diffusion and partitioning parameters of the permeating drug. This analysis enabled the efficacies of the different formulations tested to be compared to the no-enhancer control. While it was found that the formulation containing 5% oleic acid significantly enhanced the SC availability of TBF, the other formulations did not improve the apparent drug delivery. CONCLUSIONS A facile and minimally invasive methodology to evaluate an important aspect of topical drug bioavailability has been described. The analytical methods used (infrared spectroscopy and HPLC) allow estimates of both relative and absolute drug bioavailability in the SC and may be useful, therefore, in the critical determination of bioequivalence between topical formulations.


International Journal of Pharmaceutics | 2001

Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo

Ingo Alberti; Yogeshvar N. Kalia; Aarti Naik; Jean-Daniel Bonny; Richard H. Guy

PURPOSE The objective of this study was to determine the availability of the topical drug terbinafine (TBF) in human stratum corneum (SC) in vivo following its administration in formulations containing isopropyl myristate and ethanol. METHODS The ventral forearms of human volunteers were treated for 4 h with TBF, at a concentration equal to 1/4 saturation, in isopropyl myristate (IPM), in ethanol (EtOH) and in 50:50 v/v IPM/EtOH. At the end of the application period, the treated sites were carefully cleaned of excess vehicle and the SC was progressively removed by sequential tape stripping. TBF was quantified in the SC by: (a) extraction of the tape strips and subsequent HPLC analysis; and (b) attenuated total reflectance infrared spectroscopy (ATR-FTIR) of each sequentially exposed SC surface during the tape stripping procedure. RESULTS The concentration profile of TBF in the SC (i.e. drug concentration as a function of depth in the membrane) was fitted to the appropriate solution of Ficks second law of diffusion, allowing thereby the drugs SC/vehicle partition coefficient (K) and characteristic diffusion parameter (D/L(2), where D is the diffusivity of TBF in the SC of thickness L) to be deduced. CONCLUSIONS While D/L(2) for TBF derived from the three vehicles remained essentially constant, the drugs partitioning into the SC was significantly higher from formulations containing ethanol. Both the semi-quantitative infrared data and the more rigorous HPLC results supported these deductions.


Journal of Controlled Release | 2000

Poly(ethylene carbonate) microspheres: manufacturing process and internal structure characterization

Olivier Lambert; Oscar Nagele; Veronique Loux; Jean-Daniel Bonny; Laurent Marchal-Heussler

The granulocyte-macrophage colony stimulating factor (GM-CSF), a water-soluble cytokine, was encapsulated in poly(ethylene carbonate) microspheres (MS) by a double emulsion w(1)/o/w(2) solvent evaporation method. Poly(ethylene carbonate) is a new polymer of high molecular weight (MW) and forms polymer matrices that are exclusively surface bioerodible. In the frame of this study, the influence of the polymer molecular weight and the polymer concentration in the organic phase on the physico-chemical characteristics of the microspheres were investigated. Ninety percent of the microspheres had a diameter ranging between 4 and 136 microm, with a mean value of 30 microm. The encapsulation ratios ranged from 2.22 to 2.51% (w/w) depending on the molecular weight of the polymer corresponding to an encapsulation efficiency of 70 to 100%, respectively. Independent of the polymer molecular weight used, the in vitro drug release was very low, ranging from 5.61 to less than 1% of the total encapsulated GM-CSF amount. Scanning electron microscopy (SEM) analysis showed microparticles with spherical shapes and smooth surfaces containing a few small globules. The inner structure of the microspheres appeared to consist of a polymeric matrix surrounding numerous globules. These globules have different sizes, shape and distribution in the polymeric matrix, depending on the concentration of the polymer solution and on the polymer molecular weight. In addition, it was demonstrated that the GM-CSF lowered the interfacial tension between the GM-CSF aqueous solution and the methylene chloride organic phase. The active critical concentration was as low as 0.008 mg/ml. It was therefore suggested that this particular behavior contributed to the stabilization of the primary emulsion during the formation of the microspheres, leading to rather high encapsulation efficiency.


Archive | 2003

Modified release formulations of oxcarbazepine and derivatives thereof

Marie-Christine Wolf; Oskar Kalb; Jean-Daniel Bonny; Stefan Hirsch


Archive | 2002

Pharmaceutical compositions containing terbinafin and use thereof

Rainer Alles; Dieter Becker; Jean-Daniel Bonny; Stefan Hirsch; Oskar Kalb; Ernst Ulrich Kölle; Friedrich Karl Mayer; Anton Stütz; Anthony Williams


Archive | 2006

Combine capsule and tablets

Jean-Daniel Bonny; Stefan Hirsch; Oskar Kalb; Peter Pietzonka


Archive | 2002

Pharmaceutical compositions containing terbinafine and use thereof

Rainer Alles; Dieter Becker; Jean-Daniel Bonny; Stefan Hirsch; Oskar Kalb; Ernst Ulrich Kölle; Friedrich Karl Mayer; Anton Stütz; Anthony Williams


Archive | 2011

Pharmaceutical composition including octreotide microparticle

Michael Ausborn; Jean-Daniel Bonny; Olivier Lambert; Rolf Loeffler; Holger Petersen; オリヴィエ・ランベール; ジャン−ダニエル・ボニー; ホルガー・ペーターゼン; ミヒャエル・アウスボルン; ロルフ・レフラー


Archive | 2008

Pharmaceutical compositions and use thereof

Rainer Alles; Dieter Becker; Jean-Daniel Bonny; Stefan Hirsch; Oskar Kalb; Ernst Ulrich Kölle; Friedrich Karl Mayer; Anton Stütz; Anthony Williams


Archive | 2008

Pharmaceutical compositions containing terbinafineand use thereof

Rainer Alles; Dieter Becker; Jean-Daniel Bonny; Stefan Hirsch; Oskar Kalb; Ulrich Koille Ernst; Karl Mayer Friedrich; Anton Stuetz; Anthony Williams

Collaboration


Dive into the Jean-Daniel Bonny's collaboration.

Researchain Logo
Decentralizing Knowledge